Milena S. Nicoloso

Aviano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.

Journal: Signal transduction and targeted therapy

Published: January 20, 2026

Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial.

Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial.

Journal: NPJ precision oncology

Published: June 05, 2025

USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.

USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.

Journal: Science advances

Published: November 13, 2024

Author Correction: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.

Author Correction: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.

Journal: EMBO molecular medicine

Published: July 12, 2024

LINC01605 Is a Novel Target of Mutant p53 in Breast and Ovarian Cancer Cell Lines.

LINC01605 Is a Novel Target of Mutant p53 in Breast and Ovarian Cancer Cell Lines.

Journal: International journal of molecular sciences

Published: August 09, 2023

Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.

Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.

Journal: EMBO molecular medicine

Published: July 03, 2023

Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.

Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.

Journal: Viruses

Published: May 12, 2023

Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).

Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).

Journal: Gynecologic oncology

Published: July 08, 2022

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: July 02, 2022

Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.

Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 19, 2020

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.

Journal: The Journal of pathology

Published: May 22, 2020

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Journal: International journal of molecular sciences

Published: April 23, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026